Management of post-transplant lymphoproliferative disorder in adult solid organ transplant recipients - BCSH and BTS Guidelines.
A joint working group established by the Haemato-oncology subgroup of the British Committee for Standards in Haematology (BCSH) and the British Transplantation Society (BTS) has reviewed the available literature and made recommendations for the diagnosis and management of post-transplant lymphoproliferative disorder in adult recipients of solid organ transplants. This review details the therapeutic options recommended including reduction in immunosuppression (RIS), transplant organ resection, radiotherapy and chemotherapy. Effective therapy should be instituted before progressive disease results in declining performance status and multi-organ dysfunction. The goal of treatment should be a durable complete remission with retention of transplanted organ function with minimal toxicity.
Parker
Anne
A
The Beatson, West of Scotland Cancer Centre, Glasgow, UK. bcsh@b-s-h.org.uk
Bowles
Kristin
K
Bradley
J Andrew
JA
Emery
Vincent
V
Featherstone
Carrie
C
Gupte
Girish
G
Marcus
Robert
R
Parameshwar
Jayan
J
Ramsay
Alan
A
Newstead
Charles
C
D000328:Adult; D000465:Algorithms; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents / Q000627:therapeutic use; D003131:Combined Modality Therapy; D004334:Drug Administration Schedule; D019317:Evidence-Based Medicine / Q000379:methods; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000009:adverse effects; D016219:Immunotherapy, Adoptive / Q000379:methods; D008232:Lymphoproliferative Disorders / Q000209:etiology / Q000628:therapy*; D016377:Organ Transplantation / Q000009:adverse effects*; D011379:Prognosis; D012086:Reoperation; D000069283:Rituximab
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D007166:Immunosuppressive Agents; D000069283:Rituximab